The effect of ovarian puncture on the endocrine profile of PCOS patients who undergo IVM

Reproductive Biology and Endocrinology

Michel De Vos²  Johan Smitz¹  Herman Tournaye²  Luis Guzman¹  Ellen Anckaert¹  Nikolaos P Polyzos²  Carolina Ortega-Hrepich² 

[1] Laboratory of Clinical Chemistry and Radioimmunology, UZ Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium;Centre for Reproductive Medicine, UZ Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium

关键词: Total testosterone;    Sex hormone-binding globulin;    Immature oocyte retrieval;    In-vitro maturation;    Anti-Müllerian hormone;   

Others  :  804591
DOI  :  10.1186/1477-7827-12-18

 received in 2013-10-12, accepted in 2014-02-01,  发布年份 2014

【 摘 要 】

Background

To examine whether ovarian puncture for immature oocyte retrieval and in-vitro maturation (IVM) has an effect on the endocrine profile of patients with polycystic ovary syndrome (PCOS).

Methods

Twenty-two consecutive patients with PCOS undergoing IVM treatment were included. Serum anti-Müllerian hormone (AMH), sex hormone-binding globulin (SHBG), total testosterone (TT) and luteinized hormone (LH) levels were analyzed at the start of the cycle, on the day of immature oocyte retrieval (OR) and at fixed intervals thereafter, for up to three months after OR.

Results

Five days after OR circulating AMH, TT, calculated free testosterone (FTc), and LH levels were significantly reduced and circulating SHBG was significantly increased. Two weeks after OR, TT, FTc and LH remained reduced, whereas circulating AMH and SHBG levels recovered to pre-puncture values. Three months after OR, all circulating hormone levels had recovered to baseline values.

Conclusion

Ovarian puncture for the retrieval of immature oocytes and IVM in patients with PCOS has a significant impact on the ovarian endocrine profile, but this impact is brief and transient.

【 授权许可】

   
2014 Ortega-Hrepich et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Humaidan P, Quartarolo J, Papanikolaou EG: Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril 2010, 94:389-400.
• [2]Marci R, Senn A, Dessole S, Chanson A, Loumaye E, De Grandi P, Germond M: A low-dose stimulation protocol using highly purified follicle-stimulating hormone can lead to high pregnancy rates in in vitro fertilization patients with polycystic ovaries who are at risk of a high ovarian response to gonadotropins. Fertil Steril 2001, 75:1131-1135.
• [3]Devroey P, Polyzos NP, Blockeel C: An OHSS-free clinic by segmentation of IVF treatment. Hum Reprod 2011, 26:2596-2597.
• [4]Seyhan A, Ata B, Polat M, Son W-Y, Yarali H, Dahan MH: Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. Hum Reprod 2013, 28:2522-2528.
• [5]Huang JYJ, Chian RC, Tan SL: Ovarian hyperstimulation syndrome prevention strategies: in vitro maturation. Semin Reprod Med 2010, 28:519-531.
• [6]Agdi M, Zarei A, Al-Sannan B, Tulandi T, Tan SL: Effects of ovarian puncture for in vitro maturation on subsequent in vitro fertilization cycle in women with polycystic ovaries. Fertil Steril 2010, 94:381-383.
• [7]Farquhar C, Brown J, Marjoribanks J: Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev 2012, 6:CD001122.
• [8]Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004, 18:19-25.
• [9]Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004, 19:41-47.
• [10]De Vos M, Ortega Hrepich C, Albuz FK, Guzman L, Polyzos NP, Smitz J, Devroey P: Clinical outcome of non-hCG-primed oocyte in vitro maturation treatment in patients with polycystic ovaries and polycystic ovary syndrome. Fertil Steril 2011, 96:860-864.
• [11]Guzman L, Adriaenssens T, Ortega-Hrepich C, Albuz FK, Mateizel I, Devroey P, De Vos M, Smitz J: Human antral follicles <6 mm: a comparison between in vivo maturation and in vitro maturation in non-hCG primed cycles using cumulus cell gene expression. Mol Hum Reprod 2012, 19:7-16.
• [12]Vermeulen A, Verdonck L, Kaufman JM: A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999, 84:3666-3672.
• [13]Farquhar C, Lilford RJ, Marjoribanks J, Vandekerckhove P: Laparoscopic “drilling” by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev 2007. Issue 3. Art. No.: CD001122. doi:10.1002/14651858.CD001122.pub3
• [14]Armar NA, Lachelin GC: Laparoscopic ovarian diathermy: an effective treatment for anti-oestrogen resistant anovulatory infertility in women with the polycystic ovary syndrome. Br J Obstet Gynaecol 1993, 100:161-164.
• [15]Gjønnaess H: Late endocrine effects of ovarian electrocautery in women with polycystic ovary syndrome. Fertil Steril 1998, 69:697-701.
• [16]Elmashad AI: Impact of laparoscopic ovarian drilling on anti-Müllerian hormone levels and ovarian stromal blood flow using three-dimensional power Doppler in women with anovulatory polycystic ovary syndrome. Fertil Steril 2011, 95:2342-2346.
• [17]Amer SAK, Gopalan V, Li TC, Ledger WL, Cooke ID: Long term follow-up of patients with polycystic ovarian syndrome after laparoscopic ovarian drilling: clinical outcome. Hum Reprod 2002, 17:2035-2042.
• [18]Son W-Y, Chung J-T, Herrero B, Dean N, Demirtas E, Holzer H, Elizur S, Chian RC, Tan SL: Selection of the optimal day for oocyte retrieval based on the diameter of the dominant follicle in hCG-primed in vitro maturation cycles. Hum Reprod 2008, 23:2680-2685.
• [19]Shalom-Paz E, Marzal A, Wiser A, Almog B, Reinblatt S, Tulandi T, Holzer H: Effects of different body mass indices on in vitro maturation in women with polycystic ovaries. Fertil Steril 2011, 96:336-339.
• [20]Vitek WS, Witmyer J, Carson SA, Robins JC: Estrogen-suppressed in vitro maturation: a novel approach to in vitro maturation. Fertil Steril 2013, 99:1886-1890.
• [21]Fanchin R, Schonäuer LM, Righini C, Frydman N, Frydman R, Taieb J: Serum anti-Müllerian hormone dynamics during controlled ovarian hyperstimulation. Hum Reprod 2003, 18:328-332.
• [22]La Marca A, Malmusi S, Giulini S, Tamaro LF, Orvieto R, Levratti P, Volpe A: Anti-Müllerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation. Hum Reprod 2004, 19:2738-2741.
• [23]Baarends WM, Hoogerbrugge JW, Post M, Visser JA, De Rooij DG, Parvinen M, De Rooij DG, Parvinen M, Themmen AP, Grootegoed JA: Anti-müllerian hormone and anti-müllerian hormone type II receptor messenger ribonucleic acid expression during postnatal testis development and in the adult testis of the rat. Endocrinology 1995, 136:5614-5622.
• [24]Pellatt L, Hanna L, Brincat M, Galea R, Brain H, Whitehead S, Mason H: Granulosa cell production of anti-Müllerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab 2007, 92:240-245.
• [25]Smitz J, Andersen AN, Devroey P, Arce JC, MERIT Group: Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients. Hum Reprod 2007, 22:676-687.
• [26]Amer SA, Li TC, Ledger WL: The value of measuring anti-Mullerian hormone in women with anovulatory polycystic ovary syndrome undergoing laparoscopic ovarian diathermy. Hum Reprod 2009, 24:2760-2766.
• [27]Amer SAKS, Banu Z, Li TC, Cooke ID: Long-term follow-up of patients with polycystic ovary syndrome after laparoscopic ovarian drilling: endocrine and ultrasonographic outcomes. Hum Reprod 2002, 17:2851-2857.
• [28]Mio Y, Toda T, Tanikawa M, Terado H, Harada T, Terakawa N: Transvaginal ultrasound-guided follicular aspiration in the management of anovulatory infertility associated with polycystic ovaries. Fertil Steril 1991, 56:1060-1065.
• [29]Ferraretti AP, Gianaroli L, Magli MC, Iammarrone E, Feliciani E, Fortini D: Transvaginal ovarian drilling: a new surgical treatment for improving the clinical outcome of assisted reproductive technologies in patients with polycystic ovary syndrome. Fertil Steril 2001, 76:812-816.
• [30]Frantz A, Ferreira M, Hoher M, Bos-Mikich A: Spontaneous pregnancies after ovarian punctures for in vitro maturation in women with polycystic ovary syndrome. Rev Bras Ginecol Obstet 2009, 31:138-141.
• [31]Elizur SE, Son W-Y, Clarke H, Morris D, Gidoni Y, Demirtas E, Tan SL: A unique biological in-vivo model to evaluate follicular development during in-vitro maturation treatment. Reprod BioMed Online 2011, 22:257-262.
• [32]Amer S: Ovulation induction using laparoscopic ovarian drilling in women with polycystic ovarian syndrome: predictors of success. Hum Reprod 2004, 19:1719-1724.
• [33]Albuz FK, Sasseville M, Lane M, Armstrong DT, Thompson JG, Gilchrist RB: Simulated physiological oocyte maturation (SPOM): a novel in vitro maturation system that substantially improves embryo yield and pregnancy outcomes. Hum Reprod 2010, 25:2999-3011.